About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Single Ascending Dose Study of AMG 570 in Healthy Subjects

NCT02618967·3 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Amgen

Age

18–65

Sex

ALL

Healthy volunteers

Accepted

You may be eligible if

Healthy as determined by the investigator
Normal or clinically acceptable electrocardiogram (ECG)
Female subjects must be of documented non-reproductive potential
Subjects must be current for all vaccinations

You may not be if

Current or chronic history of liver disease
History of active infections
History of significant respiratory disorder
Evidence of renal disease

The record

StatusCompleted

PhasePhase 1

Taking part56

StartedMar 2016

UpdatedMay 14, 2024

Conditions

Systemic Lupus Erythematosus

Where3

Research Site
Evansville, Indiana, United States
Research Site
Overland Park, Kansas, United States
Research Site
Madison, Wisconsin, United States

Clareo Health | Single Ascending Dose Study of AMG 570 in Healthy Subjects